Exemestane vs Nandrolone
FDA Approved vs FDA Approved
avoid Mechanism-based · 75% Both Exemestane and Nandrolone carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Exemestane Nandrolone
Weight 296.40 Da 274.40 Da (base)
Half-life ~24 hours ~6-12 days (decanoate)
Type Steroidal aromatase inhibitor (irreversible, suicide inhibitor) 19-nortestosterone steroid (C18H26O2)
Key Benefits
Exemestane
01 Irreversible aromatase inactivation eliminates estrogen rebound upon discontinuation
02 Steroidal structure with mild androgenic activity may offset some low-estrogen side effects
03 Potent estrogen suppression (85-95% reduction in estradiol at full dose)
04 Compatible with tamoxifen (unlike anastrozole, no pharmacokinetic interference)
05 Prevents gynecomastia during testosterone or aromatizable steroid cycles
06 Reduces estrogen-driven water retention, bloating, and blood pressure elevation
07 Oral dosing with once-daily or less frequent administration for cycle support
Nandrolone
01 Significant increases in lean muscle mass with a favorable anabolic-to-androgenic ratio
02 Enhanced collagen synthesis and joint lubrication, reducing joint pain and improving connective tissue integrity
03 Increased bone mineral density through direct osteoblast stimulation
04 Improved nitrogen retention and protein synthesis for accelerated recovery
05 Stimulation of erythropoietin production, increasing red blood cell mass and oxygen delivery
06 Lower androgenic side effects (hair loss, acne, prostate enlargement) compared to testosterone
07 Clinically demonstrated efficacy in treating anemia of chronic renal failure
08 Potential neuroprotective properties observed in preclinical research
Dosing Protocols
Exemestane
12.5mg EOD or 25mg E3D (estrogen management) / Every other day to every 3 days (cycle support); daily (breast cancer)
Nandrolone
100-200 mg/week (therapeutic) / 1x per week (decanoate) or 2-3x per week (NPP)
TRT Adjunct - Joint Support 50-100 mg/week 1x per week (decanoate)
Therapeutic - Anemia / Wasting 100-200 mg/week 1x per week (decanoate)
Performance Enhancement - Moderate 200-400 mg/week 1x per week (decanoate) or split into 2 injections
NPP Protocol - Shorter Cycle 200-350 mg/week Every other day or 3x per week
Side Effects
Exemestane
Joint pain and stiffness (generally less severe than with anastrozole due to mild androgenic activity)
Fatigue and general malaise
Hot flashes or flushing
Mood changes (irritability, flat affect, low mood)
Headache
Increased sweating
Nandrolone
Suppression of natural testosterone production (profoundly suppressive, more so than testosterone alone)
Water retention and bloating (less than testosterone at equianabolic doses)
Erectile dysfunction and reduced libido without concurrent testosterone ('deca dick')
Increased appetite and weight gain
Mild acne and oily skin (less pronounced than testosterone)
Elevated hematocrit and hemoglobin (erythrocytosis)
Injection site pain or discomfort
Mild mood changes (some users report increased emotional sensitivity)
Contraindications
Known hypersensitivity to exemestane or any excipients
Premenopausal women (not indicated and potentially harmful to reproductive function)
Pregnancy or breastfeeding (teratogenic risk)
Severe hepatic impairment
Pre-existing severe osteoporosis or high fracture risk
Concurrent use with other aromatase inhibitors (anastrozole, letrozole)
Prostate cancer (active or history of hormone-sensitive prostate cancer)
Breast cancer in males or females
Pregnancy or potential for pregnancy (Category X - causes virilization of female fetus)
Nephrosis or the nephrotic phase of nephritis
Severe hepatic impairment
Hypercalcemia
Known hypersensitivity to nandrolone or any formulation components
Polycythemia (hematocrit above 54% at baseline)
Uncontrolled heart failure or severe cardiovascular disease
Research Evidence
Exemestane Nandrolone
Status FDA Approved FDA Approved
References 5 studies 5 studies
Latest — April 2005
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.